Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



25th January 2024

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400001

National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Scrip Code: BSE – AJANTPHARM 532331

Scrip Code: NSE AJANTPHARM EQ

Ref.: Intimation under Regulation 29(1)(e) and 42 of the Listing Regulations

Subject: Notice of the meeting of Board of Directors to consider dividend on equity shares of the company

Dear Sirs/Madam,

This is with reference to our letter dated 19th January 2024, informing about the Board meeting scheduled on Wednesday, 31st January 2024 to *inter-alia* consider and take on record the unaudited financial results for the third quarter ended 31st December 2023.

Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, we hereby inform that, at the aforesaid Board Meeting, the Board of Directors will also consider:

- a. declaration of 2nd interim dividend for the financial year ending 31st March 2024;
- b. fixation of Thursday, 8th February 2024 as the Record Date for the payment of 2nd interim dividend, if declared.

You are requested to please take a note of the above and disseminate to all concerned.

Thanking you,

Yours faithfully,

Gaurang Shah

VP – Legal & Company Secretary